Clinical trial
A Single-center, Single-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
NCT07014488 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Single-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 20, 2025
- Completion date
- August 1, 2025
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer